Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.

MoonLake’s market cap was $2.6 billion when trading stopped yesterday but climbed on news of Merck’s interest, with the stock rising almost 18% in premarket trading to send the biotech’s ...

MoonLake shares climbed 5.5% from $39.01 to $41.16 on June 2, the day news of Merck’s interest in MoonLake surfaced, then jumped another 24% over two days to $51.05 Wednesday before fading 4% to ...

Merck has held talks over a more than $3bn acquisition of Swiss biotechnology group MoonLake Immunotherapeutics, as the US pharmaceutical company seeks to replenish its drug pipeline.

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter. MoonLake's ...